MindWalk’s (HYFT) “Buy” Rating Reiterated at HC Wainwright

MindWalk (NASDAQ:HYFT)‘s stock had its “buy” rating reissued by analysts at HC Wainwright in a research note issued to investors on Tuesday,Benzinga reports. They presently have a $5.00 target price on the stock. HC Wainwright’s price objective suggests a potential upside of 304.86% from the company’s current price.

A number of other analysts have also weighed in on HYFT. Zacks Research upgraded shares of MindWalk from a “strong sell” rating to a “hold” rating in a research report on Monday, February 16th. JonesTrading started coverage on MindWalk in a report on Thursday, April 16th. They set a “buy” rating and a $5.00 price objective on the stock. Finally, UBS Group restated a “buy” rating on shares of MindWalk in a research report on Friday, March 13th. One analyst has rated the stock with a Strong Buy rating, two have issued a Buy rating, one has assigned a Hold rating and one has assigned a Sell rating to the stock. Based on data from MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and a consensus price target of $5.00.

MindWalk Stock Down 2.0%

Shares of NASDAQ:HYFT traded down $0.03 during midday trading on Tuesday, hitting $1.24. The stock had a trading volume of 76,511 shares, compared to its average volume of 400,359. The stock has a 50-day moving average price of $1.20. MindWalk has a fifty-two week low of $0.48 and a fifty-two week high of $3.25. The company has a quick ratio of 3.64, a current ratio of 3.74 and a debt-to-equity ratio of 0.21. The company has a market capitalization of $57.01 million, a P/E ratio of -6.18 and a beta of 0.65.

MindWalk (NASDAQ:HYFT) last announced its quarterly earnings data on Thursday, March 12th. The company reported ($0.06) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.04) by ($0.02). MindWalk had a negative net margin of 66.79% and a negative return on equity of 69.37%. The firm had revenue of $3.00 million during the quarter, compared to the consensus estimate of $3.50 million. Research analysts expect that MindWalk will post -0.23 EPS for the current fiscal year.

Institutional Inflows and Outflows

Several large investors have recently bought and sold shares of the stock. Renaissance Technologies LLC increased its stake in shares of MindWalk by 8.4% in the fourth quarter. Renaissance Technologies LLC now owns 239,080 shares of the company’s stock valued at $435,000 after buying an additional 18,600 shares during the period. Jane Street Group LLC lifted its stake in shares of MindWalk by 147.3% in the fourth quarter. Jane Street Group LLC now owns 161,202 shares of the company’s stock worth $293,000 after acquiring an additional 96,018 shares during the period. XTX Topco Ltd boosted its holdings in MindWalk by 118.6% in the fourth quarter. XTX Topco Ltd now owns 81,721 shares of the company’s stock valued at $149,000 after acquiring an additional 44,331 shares during the last quarter. Bank of Montreal Can increased its position in MindWalk by 81.0% during the 4th quarter. Bank of Montreal Can now owns 54,750 shares of the company’s stock valued at $100,000 after purchasing an additional 24,500 shares during the period. Finally, Bridgeway Capital Management LLC acquired a new stake in MindWalk during the 4th quarter valued at approximately $91,000. 6.70% of the stock is owned by institutional investors.

MindWalk Company Profile

ImmunoPrecise Antibodies Ltd., together with its subsidiaries, engages in antibody production and related services in the United States, Canada, Europe, and internationally. The company offers a range of antibodies, enzymes, enzyme activity assays, arthritis animal products, proteins, deiminated proteins, organoid growth factors, and hybridoma products for research purposes. Its services include custom antigen modeling, design, and manufacturing; B cell sorting, screening, and sequencing; custom, immune, and naive phage display production and screening; transgenic animals and multi-species antibody discovery; bi-specific, tri-specific, VHH, and VNAR (shark) antibody manufacturing; DNA cloning, protein and antibody downstream processing; antibody characterization on label-free biosensors and antibody engineering; transient and stable cell line generation; antibody optimization and humanization; hybridoma production with multiplexed, high-throughput screening, and clone-picking; and cryopreservation.